{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:58:16Z","timestamp":1790780296307,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T00:00:00Z","timestamp":1278460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine the prescribing of prochlorperazine secondary to the prescribing of a medicine which could lead to symptoms for which prochlorperazine is indicated and commonly used. Given the range of potential hypotensive, sedative, dystonic and other extra\u2010pyramidal side effects associated with prochlorperazine, its association with hip fracture was also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prescription\/event sequence symmetry analyses were undertaken from 1st January 2003 to 31st December 2006, using administrative claims data from the Department of Veterans' Affairs, Australia. This method assesses asymmetry in the distribution of an incident event (either prescription of another medicine or hospitalization) before and after the initiation of prochlorperazine. Crude and adjusted sequence ratios (ASR) with 95% confidence intervals (CI) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 34\u2009235 persons with incident use of prochlorperazine were identified during the study period. Statistically significant positive associations were found for a number of commonly used medicines, including cardiovascular medicines, NSAIDs, opioids and sedatives and the subsequent initiation of prochlorperazine that ranged from 1.07 (95%CI 1.01\u20131.14) for diuretics to 1.50 (95%CI 1.40\u20131.61) for statins. Prescription event analysis showed a 49% (95%CI 1.19\u20131.86) increased risk of hospitalisation for hip fracture following dispensing of prochlorperazine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prescribers should consider the possible contributing role of newly initiated medicines with the potential to cause of dizziness, and where possible address this through dose reduction or cessation of the medicine, rather than prescribing prochlorperazine. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.2009","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T13:39:43Z","timestamp":1278509983000},"page":"977-982","source":"Crossref","is-referenced-by-count":66,"title":["Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing?"],"prefix":"10.1002","volume":"19","author":[{"given":"Gillian E.","family":"Caughey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Roughead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Shakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes I.","family":"Vitry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39503.424653.80"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7115.1096"},{"key":"e_1_2_6_4_2","volume-title":"Therapeutic Guidelines: neurology. Version 3","author":"Neurology Expert Group","year":"2007"},{"key":"e_1_2_6_5_2","unstructured":"Australian Government Department of Health and Ageing. Australian Statistics on Medicines 2007. ACT: commonwealth of Australia 2007."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.01.015"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(99)80048-1"},{"key":"e_1_2_6_8_2","volume-title":"Pharmacology","author":"Rang HP","year":"2003"},{"key":"e_1_2_6_9_2","volume-title":"Australian Medicines Handbook 2008","author":"Australian Medicines Handbook","year":"2009"},{"key":"e_1_2_6_10_2","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology.Anatomical Therapeutic Chemical Code Classification index with Defined Daily Doses.http:\/\/www.whocc.no\/atcddd\/[Accessed 25th June 2009]."},{"key":"e_1_2_6_11_2","unstructured":"Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. PBS for health professionals. 2008.http:\/\/www.pbs.gov.au\/html\/healthpro\/home[Accessed 25th June 2009]."},{"key":"e_1_2_6_12_2","volume-title":"International statistical classification of diseases and related health problems, Tenth Revision, Australian Modification (ICD\u201010\u2010AM)","author":"National Centre for Classification in Health","year":"2004"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199609000-00005"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1736"},{"key":"e_1_2_6_15_2","volume-title":"Modern epidemiology","author":"Rothman K","year":"1986"},{"key":"e_1_2_6_16_2","volume-title":"The Australian Pharmaceutical Formulary and Handbook","author":"Pharmaceutical Society of Australia","year":"2006"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932020-00004"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1389"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2008.09.005"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2005.00629.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60716-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp093"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0826-5"},{"key":"e_1_2_6_24_2","volume-title":"Therapeutic Guidelines: psychotropic. Version 6","author":"Psychotropic Expert Group","year":"2008"},{"key":"e_1_2_6_25_2","unstructured":"Australian Institute of Health and Welfare (AIHW).Australian hospital statistics 2006\u201007. Health services series no 31. Cat. no. HSE 55 Canberra: Australian Government AIHW http:\/\/www.aihw.gov.au\/publications\/index.cfm\/title\/10305[Accessed 1st July 2009] 2008."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050222"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp266"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1997-y"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199811\/12)7:6<399::AID-PDS385>3.0.CO;2-C"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1250"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00862.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP42103"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2009","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.2009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T12:34:22Z","timestamp":1696768462000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,7]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1002\/pds.2009"],"URL":"https:\/\/doi.org\/10.1002\/pds.2009","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,7]]}}}